Orthofix Inc OFIX-5000-001 Benutzerhandbuch

Seite von 24
14
100
80
60
40
20
0
92%
68%
% Patients Fused
Active                    Placebo
Adjunct Clinical Trial:  Overall Success Rate
Consistent users (n=64) of the device in this phase had an initial success 
rate of 92.2% with a success rate of 70% after four years (a 24% reduction). 
Inconsistent users (n=34) and the entire placebo group (n=97) had an 
initial success rate of 65% with a success rate of 50% after four years (again, 
a 24% reduction). Long-term follow-up data indicates the success rate 
differentials between active and placebo units are maintained over time. 
Long-term, consistent Spinal-Stim users benefit with a 40% increase in fusion 
success, when compared to inconsistent and placebo device users. Based 
on this analysis, the reduction in long-term success rates appears unrelated 
to treatment with the Spinal-Stim. During this four year period, 10% of the 
original patients in the randomized double-masked phase were lost to 
follow-up and are not reflected in these success rates. 
Failed Fusion Clinical Trial
Spinal-Stim was also tested for nonoperative salvage in patients presenting 
with established pseudarthrosis of lumbar fusion in an open trial. Without 
additional regrafting of fusion surgery, 67% of these cases reached a 
successful fusion with consistent (an average of at least 2 hours per day) 
PEMF treatment.
2
 
Spinal-Stim reduced smoking and multi-level fusion as risk factors in failed 
fusion patients. Consistent users showed a 67.2% success rate in non-smokers 
and a slightly lower 66.7% success rate in smokers. Users with failed single 
level fusions showed a 68% success rate and a slightly lower 66% success 
rate for failed multi-level fusions.